

ASX

ANNOUNCEMENT

4 February 2019

RESPIRI



COMPLETION OF SHARE PURCHASE PLAN OFFER

Respiri Limited (ASX:RSH) is pleased to announce that the Share Purchase Plan (SPP) of new fully paid shares at A\$0.08 per share which closed on Thursday, 31 January 2019, was very well supported by shareholders and oversubscribed by 56%. The success of the SPP demonstrates strong support from existing shareholders and follows the recent announcement of the \$3.2 million capital raising via Private Placement announced on 18 December 2018.

Applications totalling \$1,557,000 were received against a pre-defined cap of \$1,000,000. The company outlined full details of the program terms and conditions in the SPP Booklet. Remaining consistent with this process, and as the SPP has been significantly oversubscribed, applications will be scaled back accordingly with each of the applicants to receive 64% of the number of shares for which they applied.

CEO, Mario Gattino said, "Our aim with the Share Purchase Plan was to enable our loyal shareholders to increase their holdings on the same terms as the successful Private Placement to sophisticated and professional investors, together with providing additional working capital to support the launch of wheezo™ in 2019. The response has been extremely reassuring and encouraging that Respiri's shareholders share our vision.

We thank all those who participated for your ongoing support of our strategy to bring to market the world's first wheeze detection technology for asthma management."

New shares under the SPP will be issued and allotted on Monday, 11 February 2019 with holding statements to be dispatched to participating shareholders on Wednesday, 13 February 2019.

--END--

Contact:

Mario Gattino
CEO & Director
+61 3 9653 9160



About Respi Limited

Respi's mission is to help improve quality of life for millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. The Company offers sensors, mobile apps and analytics to support respiratory health management. Its world first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. Respi's innovative platform provides personalised feedback and education based on the user's data and enables the sharing of that data with caregivers and health care providers. Respi Limited's operations are based in Melbourne, Australia.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respi's current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respi only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.